Volatility Shares Trust has made a significant regulatory move by filing a post-effective amendment to delay the effectiveness of its 3x GOOGL ETF until December 13, 2026. This decision is crucial for the company as it navigates the complexities of compliance with the Securities Act of 1933 and the Investment Company Act of 1940.
Founded in Palm Beach Gardens, Florida, Volatility Shares Trust is an investment company that focuses on innovative financial products. The firm is known for its ETFs, particularly those that leverage technology stocks. The recent filing, dated November 13, 2026, reflects the company's ongoing efforts to align its offerings with regulatory standards.
According to the filing, the purpose of this amendment is solely to delay the effectiveness of the previously filed Post-Effective Amendment No. 158 related to the 3x GOOGL ETF. The filing states, "The sole purpose of this filing is to delay the effectiveness of the Registrant’s Post-Effective Amendment No. 158, as it relates to the 3x GOOGL ETF (the 'Fund'), until December 13, 2026." This indicates that the company is taking proactive steps to ensure that all regulatory requirements are met before proceeding.
This delay may affect various stakeholders, including investors looking to engage with the 3x GOOGL ETF and financial advisors who recommend such products. The investment community will be watching closely to see how this decision impacts Volatility Shares Trust's market position and compliance strategy.
Moving forward, it remains to be seen whether Volatility Shares Trust will file additional amendments or updates regarding the 3x GOOGL ETF. The current filing does not specify any further actions beyond the delayed effectiveness date.
Read Next
Jensen Quality Growth Fund adds Tyra S. Pratt as manager
FT 13353 Files Definitive Letter Certifying Registration Amendment
FT 13354 confirms registration statement amendment filing
FT 13365 Confirms Compliance with SEC Regulations
FTP 11 files definitive letter on registration statement amendment
Aptevo Therapeutics schedules special stockholder meeting





